|By PR Newswire||
|March 25, 2014 12:00 AM EDT||
DUBLIN, March 25, 2014 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/s3kv36/investigation) has announced the addition of the "Investigation Report on China Budesonide Market" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
Asthma and allergic rhinitis are both very common diseases in the world today. As the global atmosphere becomes more and more seriously contaminated, incidence of these diseases increases year by year.
Budesonide inhalation suspension (trade name ""Pulmicort Respules"") developed by Astra Zeneca was approved to market by FDA for asthma treatment in August 2000. It obtained import approval in China in November 2001. Statistics shows that there are more than 30 million asthma patients and over 0.3 billion people suffering from allergic rhinitis in China. According to CRI's investigation on certain sample hospital market in China, the CAGR of sales value of budesonide surpassed 30% from 2005 to 2010. Since 2011, market growth has slowed down, but it still maintains an annual growth rate of 18%.
In April 2013, the patent protection of asthma drug ""Pulmicort Respules"" produced by Astra Zeneca was sentenced invalid in an U.S. regional court. Industry insiders think that this has paved the way for generic drug to occupy the market.
According to CRI's market investigation, budesonide products in Chinese market are still mainly imported drugs from Astra Zeneca, but there are already some Chinese enterprises, such as Lunan Better Pharmaceutical Co., Ltd., Humanwell Healthcare (Group) Co., Ltd. and Shanghai Sine Promod Pharmaceutical Co., Ltd., producing budesonide APIs and finished drugs.
On January 15, 2013 Santarus, Inc. announced that FDA has ratifies the usage of Uceris sustained release tablets in alleviating symptoms of mild - moderate active ulcerative colitis. Uceris is a new drug developed by Santarus, Inc. and Cosmo Technologies Limited, a subsidiary of Cosmo Pharmaceuticals S.p.A. This is a new oral tablet, and its main ingredient is budesonide.
As Chinese economy develops and its environment worsens, the number of asthma and allergic rhinitis patients in China will continue to rise in the next few years. Furthermore, more indications may emerge in China. Consequently, market size of budesonide in China will therefore continue to grow.
Key Topics Covered:
1 Relevant Concepts of Budesonide
2 Market Overview of Budesonide in China
3 Investigation on Sales Value of Budesonide in China, 2009-2013
4 Investigation on Market Share of Major Budesonide Manufacturers in China, 2009-2013
5 Investigation on Market Size of Budesonide by Dosage Form in China, 2009-2013
6 Reference Price of Budesonide Produced by Different Enterprises in China Hospital Market, 2013
7 Analysis on Major Budesonide Manufacturers in China, 2009-2013
8 Prospect of China Budesonide Market, 2014-2018
- AstraZeneca Australia
- AstraZeneca plc.
- Lunan Better Pharmaceutical Co., Ltd.
- Synmosa Biopharma Corp.
For more information visit http://www.researchandmarkets.com/research/s3kv36/investigation
Media Contact: Laura Wood , +353-1-481-1716, [email protected]
SOURCE Research and Markets
Nov. 25, 2015 10:26 AM EST
Nov. 25, 2015 10:00 AM EST Reads: 425
Nov. 25, 2015 09:45 AM EST Reads: 102
Nov. 25, 2015 09:30 AM EST Reads: 266
Nov. 25, 2015 09:00 AM EST Reads: 264
Nov. 25, 2015 08:15 AM EST Reads: 343
Nov. 25, 2015 07:45 AM EST Reads: 340
Nov. 25, 2015 07:30 AM EST Reads: 246
Nov. 25, 2015 07:15 AM EST Reads: 158
Nov. 25, 2015 06:45 AM EST
Nov. 25, 2015 05:45 AM EST Reads: 375
Nov. 25, 2015 05:45 AM EST Reads: 287
Continuous processes around the development and deployment of applications are both impacted by -- and a benefit to -- the Internet of Things trend. To help better understand the relationship between DevOps and a plethora of new end-devices and data please welcome Gary Gruver, consultant, author and a former IT executive who has led many large-scale IT transformation projects, and John Jeremiah, Technology Evangelist at Hewlett Packard Enterprise (HPE), on Twitter at @j_jeremiah. The discussion...
Nov. 25, 2015 02:30 AM EST Reads: 681
Too often with compelling new technologies market participants become overly enamored with that attractiveness of the technology and neglect underlying business drivers. This tendency, what some call the “newest shiny object syndrome” is understandable given that virtually all of us are heavily engaged in technology. But it is also mistaken. Without concrete business cases driving its deployment, IoT, like many other technologies before it, will fade into obscurity.
Nov. 25, 2015 02:00 AM EST Reads: 289
In today's enterprise, digital transformation represents organizational change even more so than technology change, as customer preferences and behavior drive end-to-end transformation across lines of business as well as IT. To capitalize on the ubiquitous disruption driving this transformation, companies must be able to innovate at an increasingly rapid pace. Traditional approaches for driving innovation are now woefully inadequate for keeping up with the breadth of disruption and change facin...
Nov. 25, 2015 12:30 AM EST Reads: 417